These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

61 related articles for article (PubMed ID: 11325662)

  • 1. The irreplaceable image. Thalidomide in refractory myeloma patients: early changes in bone marrow cellularity.
    Zappasodi P; Lorenzi A; Corso A
    Haematologica; 2001 Apr; 86(4):448. PubMed ID: 11325662
    [No Abstract]   [Full Text] [Related]  

  • 2. Early changes in bone marrow morphology induced by thalidomide in refractory myeloma patients.
    Corso A; Lorenzi A; Zappasodi P; Invernizzi R; Vanelli L; Lazzarino M
    Haematologica; 2003 Aug; 88(8):958-60. PubMed ID: 12935985
    [No Abstract]   [Full Text] [Related]  

  • 3. Tumor angiogenesis in the bone marrow of multiple myeloma patients and its alteration by thalidomide treatment.
    Du W; Hattori Y; Hashiguchi A; Kondoh K; Hozumi N; Ikeda Y; Sakamoto M; Hata J; Yamada T
    Pathol Int; 2004 May; 54(5):285-94. PubMed ID: 15086832
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Influence of thalidomide on bone marrow microenvironment in refractory and relapsed multiple myeloma].
    Li J; Luo SK; Hong WD; Zhou ZH; Zou WY
    Ai Zheng; 2003 Apr; 22(4):346-9. PubMed ID: 12703985
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Role of thalidomide in the treatment of multiple myeloma].
    Mikala G; Jákó J; Vályi-Nagy I
    Orv Hetil; 2001 Aug; 142(33):1789-98. PubMed ID: 11573449
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Dynamic MRI of the bone marrow for monitoring multiple myeloma during treatment with thalidomide as monotherapy or in combination with CED chemotherapy].
    Wasser K; Moehler T; Neben K; Nosas S; Heiss J; Goldschmidt H; Hillengass J; Düber C; Kauczor HU; Delorme S
    Rofo; 2004 Sep; 176(9):1285-95. PubMed ID: 15346264
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Salvage therapy with thalidomide in patients with advanced relapsed/refractory multiple myeloma.
    Tosi P; Zamagni E; Cellini C; Ronconi S; Patriarca F; Ballerini F; Musto P; Di Raimondo F; Ledda A; Lauria F; Masini L; Gobbi M; Vacca A; Ria R; Cangini D; Tura S; Baccarani M; Cavo M
    Haematologica; 2002 Apr; 87(4):408-14. PubMed ID: 11940485
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lenalidomide in multiple myeloma.
    Richardson PG; Mitsiades C; Hideshima T; Anderson KC
    Expert Rev Anticancer Ther; 2006 Aug; 6(8):1165-73. PubMed ID: 16925483
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The combination of intermediate doses of thalidomide and dexamethasone reduces bone marrow micro-vessel density but not serum levels of angiogenic cytokines in patients with refractory/relapsed multiple myeloma.
    Hatjiharissi E; Terpos E; Papaioannou M; Hatjileontis C; Kaloutsi V; Galaktidou G; Gerotziafas G; Christakis J; Zervas K
    Hematol Oncol; 2004 Dec; 22(4):159-68. PubMed ID: 15991268
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Thalidomide therapy in patients with refractory or relapsed multiple myeloma].
    Ochiai N; Shimazaki C; Uchida R; Fuchida S; Okano A; Ashihara E; Inaba T; Fujita N; Adachi Y; Nishio A; Nakagawa M
    Rinsho Ketsueki; 2002 Dec; 43(12):1045-9. PubMed ID: 12607993
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Thalidomide with or without dexamethasone for refractory multiple myeloma].
    Boulin M; Blanchet F; Isambert N; Solary E; Solier S; Collin B; Pernot C; Durnet-Archeray MJ
    Therapie; 2002; 57(6):524-9. PubMed ID: 12666259
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Thalidomide treatment of patients with refractory myeloma in the institutes participating in the Japan Myeloma Study Group].
    Murakami H; Handa H; Imai K; Kanakura Y; Kosaka M; Sawamura M; Shimazaki C; Suzuki K; Ishii A; Takagi T; Taniwaki M; Togawa A; Hata H; Wakayama T; Takatsuki K;
    Rinsho Ketsueki; 2004 Jun; 45(6):468-72. PubMed ID: 15287523
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Unstable plasma thalidomide concentration in patients with refractory multiple myeloma.
    Kodama T; Horiuchi R; Tsukamoto N; Nojima Y; Murakami H
    Lab Hematol; 2004; 10(3):132-6. PubMed ID: 15479647
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic use of immunomodulatory drugs in the treatment of multiple myeloma.
    Raje N; Hideshima T; Anderson KC
    Expert Rev Anticancer Ther; 2006 Sep; 6(9):1239-47. PubMed ID: 17020458
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advantages of using thalidomide for the management of refractory myeloma patients.
    Corso A; Lorenzi A; Orlandi E; Astori C; Mangiacavalli S; Lazzarino M
    Haematologica; 2002 Mar; 87(3):327-8. PubMed ID: 11869949
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thalidomide alone or in combination with dexamethasone in patients with advanced, relapsed or refractory multiple myeloma and renal failure.
    Tosi P; Zamagni E; Cellini C; Cangini D; Tacchetti P; Tura S; Baccarani M; Cavo M
    Eur J Haematol; 2004 Aug; 73(2):98-103. PubMed ID: 15245508
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Leukocytoclastic vasculitis due to thalidomide in multiple myeloma.
    Yildirim ND; Ayer M; Küçükkaya RD; Alpay N; Mete O; Yenerel MN; Yavuz AS; Nalçaci M
    Jpn J Clin Oncol; 2007 Sep; 37(9):704-7. PubMed ID: 17709605
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Thalidomide in the treatment of refractory multiple myeloma: a Dutch study of 72 patients: an antitumor effect in 45%].
    Wu KL; Schaafsma MR; Lokhorst HM; Wijermans PW; van der Holt B; Sonneveld P
    Ned Tijdschr Geneeskd; 2002 Aug; 146(31):1445-8. PubMed ID: 12190011
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Therapeutic effectiveness of thalidomide to multiple myeloma and its mechanism].
    Wang M; Liu Y; Li Y; Wu H
    Zhonghua Xue Ye Xue Za Zhi; 2002 Oct; 23(10):514-6. PubMed ID: 12482346
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Single-agent thalidomide for advanced and refractory multiple myeloma].
    Okikawa Y; Takimoto Y; Noda M; Imagawa J; Katayama Y; Sakai A; Okita H; Fujimura K; Kimura A
    Rinsho Ketsueki; 2003 Jun; 44(6):368-74. PubMed ID: 12884814
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.